The global tyrosine protein kinase SYK market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Tyrosine protein kinase SYK is also known as spleen tyrosine kinase (SYK). It is a non-receptor cytoplasmic enzyme and is primarily expressed in cells of hematopoietic lineage. It contains two adjacent SH2 domains that bind to immunoreceptor tyrosine-based activation motifs (ITAMs) to activate the enzyme. The major factor driving the growth of the market is the rising prevalence of arthritis across the globe. 

According to Arthritis Org, in 2020, over 54 million adults had doctor-diagnosed arthritis with more than 1 in 4 US adults. Additionally, almost 300,000 children had arthritis in 2020. Furthermore, this disease affects more adults younger than age 65 with more than 1 in 3 people (both men and women), aged 18 to 64, having symptoms consistent with arthritis. Hence, the rising prevalence of arthritis is driving the demand for tyrosine protein kinase SYK for treatment which in turn is driving the growth of the market. Moreover, Fostamatinib was the first oral SYK inhibitor used for the treatment of rheumatoid arthritis and lymphoid malignancies.

Some major players in the market include Celgene Corp., Gilead Sciences Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2021, Kronos Bio announced that the FDA cleared its IND for next-generation spleen tyrosine kinase (SYK) inhibitor lanraplenib (LANRA) for relapsed/refractory and newly diagnosed acute myeloid leukemia (AML). 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Celgene Corp., Clevexel Pharma SAS, Gilead Sciences Inc., GlaxoSmithKline Plc, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Tyrosine Protein Kinase SYK Market Report Segment

By Type

• HMPL-523

• C-13

• CVXL-0074

• ASN-002

• FF-10102

• Others

By Application

• Anaphylactic Shock

• Arthritis

• Fallopian Tube Cancer

• Lupus Naphritis

• Other

Global Tyrosine Protein Kinase SYK Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa